{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epoetin+Alfa&page=6", "query": { "intervention": "Epoetin Alfa", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 169, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epoetin+Alfa&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epoetin+Alfa&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T09:18:03.856Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02273726", "title": "Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "CKD Anemia in Stable Dialysis Patients" ], "interventions": [ { "name": "Epoetin Alfa", "type": "DRUG" }, { "name": "Roxadustat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyntra Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 741, "start_date": "2015-01-15", "completion_date": "2018-09-19", "has_results": true, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-10-17T09:18:03.856Z", "location_count": 74, "location_summary": "Phoenix, Arizona • Pine Bluff, Arkansas • Chula Vista, California + 58 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Chula Vista", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02273726" }, { "nct_id": "NCT00367991", "title": "Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myocardial Infarction" ], "interventions": [ { "name": "Recombinant human erythropoietin alfa (drug)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "21 Years to 75 Years" }, "enrollment_count": 44, "start_date": "2006-11", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2018-01-12", "last_synced_at": "2026-10-17T09:18:03.856Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00367991" }, { "nct_id": "NCT01473407", "title": "A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Kidney Disease", "Chronic Renal Failure" ], "interventions": [ { "name": "Epoetin Hospira", "type": "BIOLOGICAL" }, { "name": "Epogen (Amgen)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 612, "start_date": "2012-01-31", "completion_date": "2014-02-11", "has_results": true, "last_update_posted_date": "2018-09-10", "last_synced_at": "2026-10-17T09:18:03.856Z", "location_count": 84, "location_summary": "Montgomery, Alabama • Tempe, Arizona • Alhambra, California + 65 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Alhambra", "state": "California" }, { "city": "Azusa", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01473407" }, { "nct_id": "NCT02811263", "title": "High-dose Erythropoietin for Asphyxia and Encephalopathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neonatal Encephalopathy", "Birth Asphyxia" ], "interventions": [ { "name": "Normal saline placebo", "type": "DRUG" }, { "name": "Erythropoietin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "24 Hours", "sex": "ALL", "summary": "Up to 24 Hours" }, "enrollment_count": 500, "start_date": "2017-01", "completion_date": "2022-04", "has_results": true, "last_update_posted_date": "2023-01-30", "last_synced_at": "2026-10-17T09:18:03.856Z", "location_count": 23, "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02811263" }, { "nct_id": "NCT00719407", "title": "Neonatal Erythropoietin in Asphyxiated Term Newborns", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypoxic-ischemic Encephalopathy" ], "interventions": [ { "name": "erythropoietin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "24 Hours", "sex": "ALL", "summary": "Up to 24 Hours" }, "enrollment_count": 24, "start_date": "2010-01", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2012-11-09", "last_synced_at": "2026-10-17T09:18:03.856Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00719407" }, { "nct_id": "NCT00267007", "title": "A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral Neuropathy, Chemotherapy-induced" ], "interventions": [ { "name": "PROCRIT 40,000 IU QW", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2006-06", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2014-06-04", "last_synced_at": "2026-10-17T09:18:03.856Z", "location_count": 28, "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Alhambra, California + 25 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00267007" }, { "nct_id": "NCT03242967", "title": "Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Dialysis-Dependent Chronic Kidney Disease" ], "interventions": [ { "name": "Vadadustat", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akebia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-08", "completion_date": "2018-02-12", "has_results": false, "last_update_posted_date": "2018-11-05", "last_synced_at": "2026-10-17T09:18:03.856Z", "location_count": 1, "location_summary": "Northridge, California", "locations": [ { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03242967" }, { "nct_id": "NCT02879305", "title": "Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anaemia", "Aspergillosis, Allergic Bronchopulmonary" ], "interventions": [ { "name": "Daprodustat", "type": "DRUG" }, { "name": "rhEPO", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Iron therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 2964, "start_date": "2016-09-28", "completion_date": "2020-11-09", "has_results": true, "last_update_posted_date": "2021-12-03", "last_synced_at": "2026-10-17T09:18:03.856Z", "location_count": 126, "location_summary": "Huntsville, Alabama • Pine Bluff, Arkansas • Anaheim, California + 103 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02879305" }, { "nct_id": "NCT00843882", "title": "Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Chronic Myelomonocytic Leukemia", "De Novo Myelodysplastic Syndrome", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Epoetin Alfa", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 247, "start_date": "2009-04-20", "completion_date": "2027-05-28", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-17T09:18:03.856Z", "location_count": 507, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 345 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00843882" }, { "nct_id": "NCT00386152", "title": "A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Anemia", "Cancer" ], "interventions": [ { "name": "epoetin alfa", "type": "DRUG" }, { "name": "darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2006-11", "completion_date": "2008-05", "has_results": true, "last_update_posted_date": "2013-07-19", "last_synced_at": "2026-10-17T09:18:03.856Z", "location_count": 76, "location_summary": "Glendale, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 73 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00386152" } ] }